Acute Kidney Injury and its Relationship with NSAIDs and ACE Inhibitors

Slides from University about Acute Kidney Injury and its Relationship with NSAIDs and ACE Inhibitors. The Pdf explores the mechanisms through which these drugs affect renal function and the risk factors for AKI development. This Biology material is suitable for university students.

See more

40 Pages

REMINDERS/H
OUSEKEEPING:
IPE
EVENT/WORKSHO
P - week 32
PSA DEBRIEF -
Lecture week 33 -
18th March
Midday
CMISGO timetable
reminder
Objectives today
Revision
(pharmacology)
Acute Kidney Injury
(objectives for this
later)
Pre-workshop
preparation
Acute kidney injury (AKI) is associated with increased
patient morbidity and mortality, and represents a
significant financial burden for the NHS. The National
Confidential Enquiry into Patient Outcomes and Death
(NCEPOD)'s report, adding insult to injury, demonstrated
that only 50% of patients who died from
AKI received good care and 30% of
patients had predictable and avoidable
AKI. It is therefore essential to identify patients at
risk of AKI early and to treat patients who develop it
promptly.
Clinical Medicine (RCoP); 2012, Prescott et al

Unlock the full PDF for free

Sign up to get full access to the document and start transforming it with AI.

Preview

Reminders and Housekeeping

IPE
EVENT/WORKSHOP - week 32
PSA DEBRIEF -
Lecture week 33 -
18th March
Midday
CMISGO timetable
reminder

  • Objectives today


Revision
(pharmacology)
Acute Kidney Injury
(objectives for this
later
Pre-workshop
preparationAcute kidney injury (AKI) is associated with increased
patient morbidity and mortality, and represents a
significant financial burden for the NHS. The National
Confidential Enquiry into Patient Outcomes and Death
(NCEPOD)'s report, adding insult to injury, demonstrated
that only 50% of patients who died from
AKI received good care and 30% of
patients had predictable and avoidable
AKI.
It is therefore essential to identify patients at
risk of AKI early and to treat patients who develop it
promptly.
Clinical Medicine (RCoP); 2012, Prescott et al

Function of the Kidneys

  • Location?

. How many ?!
· What size?
. Nearby organs?
Liver
Spleen
0
Left
kidney
Right
kidney
Adrenal
gland
Kidney
Adrenal
gland
Cortex
Medulla
Kidney


Which blood
vessel supplies
the Kidney?

Which blood
vessel supplies
the glomerulus?

How is blood
supplied to the
Glomeruli?

What takes blood
away from the
glomeruli?

What takes blood
away from the
kidney?

Kidney Blood Supply Diagram

Peritubular capillaries
Efferent
arteriole
Glomerulus
Afferent
arteriole
Interlobular
artery
Arcuate
artery
Interlobar
artery
Interlobular
vein
Arcuate
vein
Segmental
artery
Interlobar
vein
Renal
artery
Renal vein

Key Kidney Functions

. Maintain the proper balance of water and
minerals (including electrolytes)
· Filtration & excretion of waste (food, drugs, etc)
· Regulation of BP (Na, renin, etc)
· Secretion of certain hormones (Epo, Vit D)
. Acid base balance = maintaining pH of blood

Kidney Function and Supplementation

FunctionDescription of FunctionSupplementsPurpose of Supplement if Function is Impaired
Water & Electrolyte BalanceRegulates water and electrolytes (Na+, K+, Ca2+, PO43") through filtration and reabsorption to maintain homeostasis.Potassium binders (e.g., sodium zirconium cyclosilicate, patiromer), DiureticsPrevents hyperkalemia and fluid overload (edema, hypertension).
Filtration & Waste ExcretionRemoves urea, creatinine, toxins, and drug metabolites from the blood via urine.Dialysis (if severe kidney failure)Removes toxic waste buildup when kidneys fail.
Blood Pressure RegulationControls BP by regulating sodium and water balance, and releasing renin, which activates the RAAS system to regulate vascular tone.ACE inhibitors, ARBs, DiureticsHelps lower high BP and reduce kidney damage.
Erythropoietin (EPO) SecretionProduces EPO to stimulate red blood cell (RBC) production in the bone marrow.Erythropoiesis- stimulating agents (ESAs) (e.g., Epoetin alfa, Darbepoetin alfa), Iron supplements (oral or IV)Treats anemia caused by low EPO levels in CKD.
Vitamin D ActivationConverts inactive vitamin D into its active form (calcitriol) to help regulate calcium absorption from the gut.Vitamin D supplements (Alfacalcidol, Calcitriol)Prevents renal osteodystrophy (bone disease) and hypocalcemia.
Calcium & Phosphate RegulationKidneys help regulate calcium & phosphate balance. In CKD, phosphate excretion is reduced, leading to hyperphosphatemia, which causes bone and vascular damage.Phosphate binders (e.g., Sevelamer, Lanthanum, Calcium acetate)Reduces high phosphate levels and prevents vascular calcification and bone disease.
Acid-Base BalanceMaintains blood pH (7.35-7.45) by excreting H+ and reabsorbing HCO3.Sodium bicarbonateCorrects metabolic acidosis caused by impaired H+ excretion.

Acute Kidney Injury (AKI) Objectives

Pharmacy Year 2 AKI Learning Goals

  • Familiarise yourself with the prevalence &
    epidemiology of AKI
  • Familiarise yourself with the symptoms, risk factors
    and diagnosis of AKI
  • Drugs which contribute to AKI
  • Be familiar with guidelines for the treatment of AKI
  • Have knowledge of the management regimens
  • Pharmacists role in AKI

AKI Presentation in Practice

  • New AKI

AKI on the
background of
CKD (CRF)
AKI in the
background of
ESRD

Definition of AKI

Acute kidney injury (AKI) is a
condition in which there is
rapid decline in kidney
function over a period of
hours to days, resulting in a
rapid reduction in kidney
function . Effectively this
means the kidney is unable to
maintain fluid, electrolyte and
acid-base homoeostasis.

Terminology & Definition of AKI

  • ARF

AKI (universal definition)
"The term acute kidney injury has replaced
the concept of acute renal failure as it more
accurately describes that injury to the kidney
can occur before function fails" [Prescott et al,
2012]
· AKI - considered to be a spectrum of injury
(next slide)
. Even small increase in SCr is associated with
decreased long term survival in the critically ill
[Linder et al 2014]

The AKI Spectrum

StageDescriptionClinical Features
1. Subclinical AKIEarly, mild injury with no clear symptoms but detectable by biomarkers.Elevated urinary biomarkers (e.g., NGAL, KIM-1) before serum creatinine rises.
2. Mild AKI (Stage 1 AKI)Minor decline in kidney function, often reversible with early intervention.Serum creatinine rises by ≥26.5 umol/L (20.3 mg/dl) within 48 hrs or 1.5-1.9x baseline. Urine output may be slightly reduced.
3. Moderate AKI (Stage 2 AKI)More significant impairment but may still recover with treatment.Serum creatinine rises 2-2.9x baseline. Urine output <0.5 ml/kg/h for ≥12 hrs.
4. Severe AKI (Stage 3 AKI)Major loss of kidney function, often requiring renal replacement therapy (RRT).Serum creatinine rises ≥3x baseline or to ≥354 umol/L (≥4.0 mg/dL). Urine output <0.3 ml/kg/h for 224 hrs or anuria (no urine) for ≥12 hrs. Dialysis may be needed.
5. AKI with Multi-Organ FailureAKI progresses to severe dysfunction, affecting other organs (e.g., heart, lungs).Sepsis, shock, multi-organ dysfunction syndrome (MODS). Poor prognosis, often in ICU settings.
6. Progression to CKD or ESRDSome AKI cases do not fully recover and lead to chronic kidney disease (CKD) or end-stage renal disease (ESRD).Persistent eGFR decline, proteinuria, or need for long-term dialysis.
  • Decreased
    glomerular
    filtration
  • Minimal
    elevations in
    serum
    creatinine
    (Cr)
  • To complete
    anuric
    kidney
    failure

Anuria is non
passage of
urine,

What is Serum Creatinine (SCr)?


Creatinine is a waste
product generated
from the normal
metabolism of muscle
tissue
. Healthy kidneys freely
filter creatinine out of
your blood through
urine

SCr is measured via a
blood test

Classification of Chronic Kidney Disease

Classification of chronic
kidney disease using GFR
and ACR categories
GFR and ACR categories
and risk of adverse
outcomes
ACR categories (mg/mmol), description and range
<3 Normal to mildly
increased
3-30 Moderately
increased
>30 Severely
increased
A1
A2
A3
>90 Normal
and high
G1
No CKD in the
absence of markers
of kidney damage
GFR categories (ml/min/1.73 m2), description and range
60-89 Mild
reduction related
to normal range
for a young adult
G2
45-59 Mild-
moderate
reduction
G3a1
30-44
Moderate-
severe reduction
G3b
15-29 Severe
reduction
G4
<15 Kidney
failure
G5
Increasing risk
Increasing risk
1 Consider using eGFRcystatinC for people with CKD G3aA1 (see KDIGO recommendations 1.1.14 and 1.1.15)
Abbreviations: ACR, albumin:creatinine ratio; CKD, chronic kidney disease; GFR, glomerular filtration rate
Adapted with permission from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO
2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International
(Suppl. 3): 1-150

Prevalence & Impact of AKI

Whilst this is partially true, in that AKI has not been picked up or
focussed on as it should have been

AKI Prevalence Data

The HES (Hospital Episode Statistics) data indicated that;
AKI was recorded for 2.4% of hospital admissions during 2010/11 (142,705 out of
3,792,951 admissions).
Prevalence ranged from 0.3% of patients aged 18 to 39, to 5.7% of people aged
≥80.
During the six-month period of EKHUFT (East Kent Hospitals University Foundation
Trust) data, laboratory research indicated that AKI was present in 15% of
admissions, though the EKHUFT population is older than the overall HES (hospital
episode statistics) population. When standardising for age, it was 14% of
admissions. Over a third of patients (38%) in EKHUFT who had AKI during the
study period had pre-existing chronic kidney disease.
When using HES data, the average duration of hospital stay was 16.5 days for AKI-
admissions, compared to just 5.1 days for admissions without AKI recorded. A
person with AKI had a length of stay 2.6 times longer than someone without AKI;
Using the HES data, just over a quarter (28%) of people with AKI recorded during
their admission died before hospital discharge. The odds of in-hospital death were
10-fold greater in a person with AKI compared to those without.
Analysis from HES data suggests that AKI was associated with around 12,000
excess deaths among inpatients in England

BBC News Report on Kidney Deaths

BBC
Sign in
News
Sport
Weather
iPlayer
NEWS
Home
UK
World
Business
Politics
Tech
Science
Health
Education
Health
Flawed NHS care 'leads to 12,000 kidney
deaths a year'
By Prof Donal O'Donoghue
Former National Clinical Director for Kidney Care
@ 21 June 2013 Health
The quality of patient care in the NHS
is once again under the spotlight as
part of the investigation into
complaints after deaths at Furness
General Hospital.
In this week's Scrubbing Up, Prof
Donal O'Donoghue, National Clinical
Director for Kidney Care from 2007-
2013, warns a simple-to-avoid kidney
disorder is being missed leading to
around 12,000 unnecessary deaths a
year.
SPL
Keeping patients hydrated is a simple way of
preventing the condition

AKI Statistics (UK)

  • Approximately one fifth of hospital admissions are
    associated with AKI [Argyropoulos et al 2019 BMC Nephrology]
  • ~ third of in-patients develop AKI during their time
    in hospital [Argyropoulos et al 2019 BMC Nephrology]
  • A fifth of these cases are considered avoidable
    [Argyropoulos et al 2019 BMC Nephrology]
  • 100,000/year deaths associated with AKI. = to ten
    people every hour [KidneycareUK]
  • A person with AKI length of stay 2.6 times longer
    than someone without AKI [HES data]

Can’t find what you’re looking for?

Explore more topics in the Algor library or create your own materials with AI.